UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

Cancer research (Chicago, Ill.), 2007-01, Vol.67 (2), p.746-755

2007

Volltextzugriff (PDF)

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

Microvascular research, 2009-03, Vol.77 (2), p.78-86

2009

Volltextzugriff (PDF)

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Blood, 2001-07, Vol.98 (1), p.210-216

2001

Volltextzugriff (PDF)

Thalidomide and Lenalidomide Extend Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

The Journal of neuroscience, 2006-03, Vol.26 (9), p.2467-2473

2006

Volltextzugriff (PDF)

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

Bioorganic & medicinal chemistry letters, 2013-01, Vol.23 (1), p.360-365

2013

Volltextzugriff (PDF)

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

The Journal of pharmacology and experimental therapeutics, 2003-06, Vol.305 (3), p.1222-1232

2003

Volltextzugriff (PDF)

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

Bioorganic & medicinal chemistry, 2011-11, Vol.19 (21), p.6356-6374

2011

Volltextzugriff (PDF)

CC-5079: A Small Molecule with MKP1, Antiangiogenic, and Antitumor Activity

The Journal of surgical research, 2010-11, Vol.164 (1), p.116-125

2010

Volltextzugriff (PDF)

Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma

Journal of translational medicine, 2007-07, Vol.5 (1), p.38-38, Article 38

2007

Volltextzugriff (PDF)

Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity

The Journal of immunology (1950), 2002-05, Vol.168 (10), p.4914-4919

2002

Volltextzugriff (PDF)

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (2), p.951-959

2006

Volltextzugriff (PDF)

Chiral inversion of the second generation IMiD™ CC-4047 (ACTIMID™) in human plasma and phosphate-buffered saline

Chirality (New York, N.Y.), 2003, Vol.15 (4), p.348-351

2003

Volltextzugriff (PDF)

A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins

Cancer research (Chicago, Ill.), 2003-02, Vol.63 (3), p.593-599

2003

Volltextzugriff (PDF)

α-Fluoro-substituted thalidomide analogues

Bioorganic & medicinal chemistry letters, 2003-10, Vol.13 (20), p.3415-3417

2003

Volltextzugriff (PDF)

Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells

Pancreas, 2009-01, Vol.38 (1), p.78-84

2009

Volltextzugriff (PDF)

Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity

Journal of medicinal chemistry, 1996-08, Vol.39 (17), p.3238-3240

1996

Volltextzugriff (PDF)

Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

Oncology research, 2003, Vol.14 (2), p.75-82

2003

Volltextzugriff (PDF)

Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition

Cancer research (Chicago, Ill.), 2003-12, Vol.63 (23), p.8073-8078

2003

Volltextzugriff (PDF)

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

The Journal of immunology (1950), 1999-07, Vol.163 (1), p.380-386

1999

Volltextzugriff (PDF)

Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production

Bioorganic & medicinal chemistry letters, 1999-06, Vol.9 (11), p.1625-1630

1999

Volltextzugriff (PDF)

Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues

Journal of clinical immunology, 2001-09, Vol.21 (5), p.357-364

2001

Volltextzugriff (PDF)

N,N'-disubstituted guanidine high-potency sweeteners

Journal of medicinal chemistry, 1992-02, Vol.35 (4), p.740-743

1992

Volltextzugriff (PDF)

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

Molecular medicine (Cambridge, Mass.), 1996-07, Vol.2 (4), p.506-515

1996

Volltextzugriff (PDF)

Carboxylic acid replacement structure-activity relationships in suosan type sweeteners. A sweet taste antagonist. 1

Journal of medicinal chemistry, 1992-05, Vol.35 (10), p.1747-1751

1992

Volltextzugriff (PDF)

Thalidomide analogs and PDE4 inhibition

Bioorganic & medicinal chemistry letters, 1998-10, Vol.8 (19), p.2669-2674

1998

Volltextzugriff (PDF)

1 – 25 von 196

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(188)
Mit Volltextzugriff
(162)

Publikationsform

Artikel
(196)

Sprache

Englisch
(196)

Erscheinungsjahr

n.n

Thema

Science & Technology
(178)
Humans
(161)
Life Sciences & Biomedicine
(160)
Female
(72)
Male
(64)
Biological And Medical Sciences
(62)
Medical Sciences
(56)
Animals
(51)
Middle Aged
(47)
Adult
(46)
Aged
(37)
Mice
(29)
Medicin Och Hälsovetenskap
(25)
Genome-Wide Association Study
(23)
Thalidomide - Analogs & Derivatives
(23)
Pharmacology. Drug Treatments
(21)
Genetics & Heredity
(20)
Risk Factors
(20)
Treatment Outcome
(20)
Genomes
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Thalidomide and Lenalidomide Extend Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

CC-5079: A Small Molecule with MKP1, Antiangiogenic, and Antitumor Activity

Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma

Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity

Chiral inversion of the second generation IMiD™ CC-4047 (ACTIMID™) in human plasma and phosphate-buffered saline

A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins

α-Fluoro-substituted thalidomide analogues

Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells

Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity

Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production

Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues

N,N'-disubstituted guanidine high-potency sweeteners

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

Carboxylic acid replacement structure-activity relationships in suosan type sweeteners. A sweet taste antagonist. 1

Thalidomide analogs and PDE4 inhibition

Aktive Filter

Suchergebnisse filtern